Positive arbitration decision on AATD rights

Research evidence excerpt

Positive arbitration decision on AATD rights

Update

July 8, 2026 02:18 PM GMT

Morgan Stanley & Co. LLCMPrime Medicine Inc | North America Terence C Flynn, Ph.D.

Equity Analyst

Positive arbitration decision on Terence.Flynn@morganstanley.comChris Yu, J.D., Ph.D. +1 212 761-2230

Chris.L.Yu@morganstanley.com +1 212 761-2535

AATD rights Damien H Kerner

Research Associate

Damien.H.Kerner@morganstanley.com +1 212 761-3829

PRME announced on July 8 a positive resolution to the arbitration with BEAM

Connor M Massari

(not covered) regarding the rights to develop a prime editing-based treatment Equity Analyst

for AATD (LINK). Per the PR, the tribunal declared that PRME did not breach the Connor.Massari@morganstanley.com +1 212 761-2417

Alexander Yevdokimov, Ph.D.

parties' 2019 collaboration agreement, and does not owe monetary damages to Research Associate

BEAM. As indicated in our Month Ahead note (LINK), we think PRME could trade up Alexander.Yevdokimov@morganstanley.com +1 212 761-2167

Hailey Horowitz

DD% as a result. PRME's AATD candidate is PM647, which leverages PRME's Research Associate

universal LNP to correct the E342K mutation in the SERPINA1 gene. PRME plans to Hailey.Horowitz@morganstanley.com +1 212 761-5264

submit an IND and/or CTA filing for PM647 in 3Q26 and expects initial clinical data in Morgan Stanley India Company Private Limited+

2027. We do not include the AATD program in our model, hence the success of this Saket Agarwal

program represents a potential source of upside to our estimates. Per PRME, there Saket.Agarwal@morganstanley.com +91 22 6995-4012

are currently no disease-modifying or curative treatments approved for the ~200k

people across the US and EU with AATD. Prime Medicine Inc (PRME.O, PRME US)

Biotechnology | United States of America